KEAP1 and neoplasm: Although genetic alterations of the Keap1/Nrf2 pathway were reported only in a small fraction of ccRCCs (6.6%) [132], tumor-specific DNA methylation of the KEAP1 gene promoter has been detected in 48.6% of the tumors [186].